Dr Reddy’s launch Capecitabine Tablets, USP in US

Capecitabine tablet is indicated for the treatment of Adjuvant Colon Cancer, Metastatic Colorectal Cancer and Metastatic Breast Cancer

Dr Reddy’s Laboratories announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA).

Capecitabine tablet is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

  • Adjuvant Colon Cancer

– Patients with Dukes’ C colon cancer

  • Metastatic Colorectal Cancer

– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred

  • Metastatic Breast Cancer

– In combination with docetaxel after failure of prior anthracycline-containing therapy

– As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.

Dr Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Capecitabine TabletsDr Reddy's Laboratoriesnucleoside metabolic inhibitorUS FDAUS Pharma market
Comments (0)
Add Comment